MagForce (MF6) - Funding in place for EU roll-out

07:07 EDT 11 Aug 2017 | Edison Investment Research

Edison Investment Research - Pharmaceutical & healthcare - MagForce: MagForce has announced a loan of up to €35m from the European Investment Bank (EIB), of which €10m is available immediately. This funding will enable MagForce to roll out its NanoTherm devices across Europe and reach patients who were previously reluctant to travel across the border to Germany for glioblastoma treatment. While we believe the extra funds could accelerate EU device roll-out above our current assumptions, we retain our forecasts and await more details on progress. Our valuation of MagForce remains unchanged at €226m (€8.6/share).

Original Article: MagForce (MF6) - Funding in place for EU roll-out


More From BioPortfolio on "MagForce (MF6) - Funding in place for EU roll-out"

Quick Search

Relevant Topic

Health care (or healthcare) is the diagnosis, treatment, and prevention of disease, illness, injury, and other physical and mental impairments in humans. Health care is delivered by practitioners in medicine, chiropractic, dentistry, nursing, pharmacy, a...